IP Library Patent Application 11255132
Patent Application
App. No. 11/255,132

Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/255,132
Abstract

Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce or have the potential for inducing abnormal production of pro-inflammatory or anti-inflammatory stimulators or mediators. The devices, systems, and methods serve to prevent, control, reduce, or alleviate the severity of the inflammatory response and disease states that are associated with abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators.

Claims (9)

1 . A method for treating an individual experiencing a condition on a continuum from early sepsis to septic shock comprising the steps of

drawing the blood from the circulatory system of the individual for return to the circulatory system, and

removing cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from the blood by bringing the blood into contact with an adsorption medium sized to selectively adsorb cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from the blood, the adsorption medium being characterized by a Biocompatibility Index of not greater than 14.

2 . A method according to claim 1

wherein the Biocompatibility Index is not greater than 7.

3 . A method according to claim 1

wherein the adsorption medium comprises a polymeric material.

4 . A method according to claim 3

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate,N-vinylpyrrolidine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2008
From: PUROLITE INTERNATIONAL LTD.; BRO-TECH CORPORATION
To: BRODIE, STEFAN; BRODIE, DONALD
Reel/Frame 021785/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2006
From: MEDASORB CORPORATION
To: BRO-TECH CORPORATION
Reel/Frame 018207/0193 →